VIRUS TODAY: Merck to produce J&J shot, Dems set to debate
Drugmaker Merck & Co. will help produce rival Johnson & Johnson’s newly approved coronavirus vaccine in an effort to expand supply more quickly
Your support helps us to tell the story
This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.
The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.
Help us keep bring these critical stories to light. Your support makes all the difference.
Here's what's happening Tuesday with the coronavirus pandemic in the U.S.:
THREE THINGS TO KNOW TODAY:
— Drugmaker Merck & Co. will help produce rival Johnson & Johnson’s newly approved coronavirus vaccine to try to expand supply more quickly.
— Democrats are sorting through lingering disagreements over emergency jobless benefits and other issues and preparing to commence Senate debate on a $1.9 trillion COVID-19 relief plan.
— A leader of the U.N.-backed project to deploy COVID-19 vaccines to the needy in both rich and poor countries acknowledges the rollout has gone slower than expected in some places because of issues with shipping and approval, but says “ultimately” all doses will be made available.
THE NUMBERS:
CASES: According to data through March 1 from Johns Hopkins University, the seven-day rolling average for daily new cases in the U.S. dropped from 85,813.9 on Feb. 15 to 67,760.3 on Monday.
DEATHS: According to data through March 1 from Johns Hopkins University, the seven-day rolling average for daily new deaths in the U.S. went from 2,361.9 on Feb. 15 to 2,046.1 on Monday.
POSITIVITY RATE: According to data through March 1 from the COVID Tracking Project, the seven-day rolling positivity rate for testing in the U.S. went from 5.6 on Feb. 15 to 4.4 on Monday.
VACCINES: 50.7 million people, or 15.3% of the U.S. population, have received at lease one dose of a coronavirus vaccine, according to the CDC, while 25.5 million people have completed their vaccination, or 7.7% of the population.
QUOTABLE: "It was allowing them to feel like it was OK to admit our sadness in this moment.” — Artist Kristina Libby , who started the Floral Heart Project to give the survivors of COVID-19 victims places to mourn.
ON THE HORIZON: The Caribbean is hunting for visitors and vaccines as it seeks to jump-start the stalled economy of one of the world’s most tourism-dependent regions. Clear waters and warm sand had attracted a record 31.5 million tourists to the region in 2019. But visits plummeted by an estimated 60% to 80% last year. Local governments are turning to India and China for vaccines to make it safe to welcome back tourists without prompting a spike in COVID-19 cases that could overwhelm their fragile health care systems.
___
Find AP’s full coverage of the coronavirus pandemic at https://apnews.com/hub/coronavirus-pandemic
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.